Literature DB >> 12389872

Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit.

Jill A Rebuck1, Douglas N Fish, Edward Abraham.   

Abstract

STUDY
OBJECTIVE: To characterize the pharmacokinetic disposition of intravenous and oral levofloxacin in critically ill adults.
DESIGN: Prospective, open-label study.
SETTING: University teaching hospital. PATIENTS: Thirty critically ill patients in a medical intensive care unit (ICU).
INTERVENTIONS: All patients received levofloxacin as part of their routine medical care. Pharmacokinetic evaluations were performed in 28 patients receiving intravenous levofloxacin. Ten of these patients subsequently were switched to oral levofloxacin and underwent a second pharmacokinetic evaluation during oral therapy.
MEASUREMENTS AND MAIN RESULTS: Mean +/- SD levofloxacin half-life, clearance at steady state, and volume of distribution in all 28 patients were 8.0 +/- 1.7 hours, 134 +/- 35 ml/minute, and 1.2 +/- 0.3 L/kg, respectively Maximum and minimum serum concentrations (Cmax and Cmin) and area under the serum concentration-time curve from 0-24 hours (AUC(0-24)) in patients receiving levofloxacin 500 mg intravenously were 7.5 +/- 0.8 mg/L, 1.0 +/- 0.5 mg/L, and 66.1 +/- 15.7 mg x hour/L, respectively Observed Cmax, Cmin, and time at which maximum concentration was achieved after oral doses of levofloxacin 500 mg were 5.5 +/- 1.1 mg/L, 0.8 +/- 0.4 mg/L, and 1.3 +/- 0.4 hours, respectively. These values were significantly different (p < 0.05) from those observed after intravenous dosing in the same patients; other pharmacokinetic parameters were similar. Statistically significant increases (p < 0.05) in Cmax, Cmin, half-life, and AUC(0-24) were found in critically ill patients administered multiple doses of intravenous levofloxacin compared with historical data from healthy volunteers.
CONCLUSIONS: The dosage regimen of intravenous levofloxacin 500 mg once/day appears adequate for most pathogens found in critically ill patients with normal renal function. Less susceptible pathogens may require an increased daily dose for more optimal therapy. Orally administered levofloxacin appears to be well absorbed in selected ICU patients and has pharmacokinetics similar to those of intravenously administered levofloxacin.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12389872     DOI: 10.1592/phco.22.15.1216.33484

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  19 in total

Review 1.  Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases.

Authors:  P S McKinnon; S L Davis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-10       Impact factor: 3.267

2.  Antibacterial efficacy of inhalable levofloxacin-loaded polymeric nanoparticles against E. coli biofilm cells: the effect of antibiotic release profile.

Authors:  Wean Sin Cheow; Matthew Wook Chang; Kunn Hadinoto
Journal:  Pharm Res       Date:  2010-04-21       Impact factor: 4.200

Review 3.  Addressing Concerns about Changing the Route of Antimicrobial Administration from Intravenous to Oral in Adult Inpatients.

Authors:  Lizanne Béïque; Rosemary Zvonar
Journal:  Can J Hosp Pharm       Date:  2015 Jul-Aug

4.  Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury.

Authors:  Tyree H Kiser; Dorie W Hoody; Marilee D Obritsch; Colleen O Wegzyn; Paulus C Bauling; Douglas N Fish
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

Review 5.  Pharmacokinetic and Pharmacodynamic Considerations of Antibiotics of Last Resort in Treating Gram-Negative Infections in Adult Critically Ill Patients.

Authors:  Mojdeh S Heavner; Kimberly C Claeys; Anne M Masich; Jeffrey P Gonzales
Journal:  Curr Infect Dis Rep       Date:  2018-04-05       Impact factor: 3.725

6.  Pharmacokinetics of intravenous levofloxacin administered at 750 milligrams in obese adults.

Authors:  Aaron M Cook; Craig Martin; Val R Adams; R Scott Morehead
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

7.  In Vitro Activity of Polymyxin B in Combination with Various Antibiotics against Extensively Drug-Resistant Enterobacter cloacae with Decreased Susceptibility to Polymyxin B.

Authors:  Yiying Cai; Tze-Peng Lim; Jocelyn Teo; Suranthran Sasikala; Winnie Lee; Yanjun Hong; Eric Chun Yong Chan; Thean Yen Tan; Thuan-Tong Tan; Tse Hsien Koh; Li Yang Hsu; Andrea L Kwa
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

8.  In vitro pharmacodynamics of various antibiotics in combination against extensively drug-resistant Klebsiella pneumoniae.

Authors:  Tze-Peng Lim; Yiying Cai; Yanjun Hong; Eric Chun Yong Chan; Sasikala Suranthran; Jocelyn Qi-Min Teo; Winnie Huiling Lee; Thean-Yen Tan; Li-Yang Hsu; Tse-Hsien Koh; Thuan-Tong Tan; Andrea Lay-Hoon Kwa
Journal:  Antimicrob Agents Chemother       Date:  2015-02-17       Impact factor: 5.191

Review 9.  Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.

Authors:  Katherine F Croom; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

10.  Quantitative assessment of combination antimicrobial therapy against multidrug-resistant Acinetobacter baumannii.

Authors:  Tze-Peng Lim; Kimberly R Ledesma; Kai-Tai Chang; Jing-Guo Hou; Andrea L Kwa; Michael Nikolaou; John P Quinn; Randall A Prince; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2008-05-27       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.